secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-043017
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata receives $4.65M additional DoD funding for phage therapy trial; topline data Q2 2025
--------------------------------------------------------------------------------

- Received $4.65M additional non-dilutive DoD funding for AP-SA02; total award now $26.2M.
- Phase 1b/2a diSArm trial of AP-SA02 for S. aureus bacteremia enrolled 50 subjects; last visit Jan 2025.
- Two subsets observed: one with in vivo phage amplification suggesting phage activity despite antibiotics.
- Topline data expected in Q2 2025 to inform optimal dose for larger efficacy trial.
- Going concern note in 2024 10-K remains unchanged per company disclosure.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/0001104659-25-043017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465925043017/tm2513778d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-043017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer